Pharmaceutical major Cipla has received a Voluntary Action Indicated (VAI) classification from the United States Food and Drug Administration (USFDA) for its manufacturing facility at Verna in Goa following an inspection conducted earlier this year.
In a regulatory filing on Thursday, the company said the USFDA had informed it through a communication dated June 10, 2026, that the inspection had been classified as VAI.
“… we hereby notify that the US FDA vide communication dated 10th June 2026 has classified the above referred inspection as Voluntary Action Indicated (VAI),” the company said.
The USFDA conducted a routine Current Good Manufacturing Practices (cGMP) inspection along with a Pre-Approval Inspection (PAI) at Cipla’s manufacturing facility in Verna between April 6 and April 17, 2026.
At the conclusion of the inspection, the regulator issued two observations in Form 483. Form 483 observations are issued when FDA investigators identify conditions that may represent deviations from current Good Manufacturing Practices. The observations themselves do not automatically trigger regulatory action and companies are generally given an opportunity to respond and implement corrective measures.
According to Cipla, the company had indicated after the inspection that it would work with the regulator and address the observations within the prescribed timeline.
Under the FDA’s inspection classification system, a facility may receive one of three outcomes. A No Action Indicated (NAI) classification means no objectionable conditions were found. A Voluntary Action Indicated (VAI) classification means objectionable conditions were identified but do not warrant regulatory or enforcement action. An Official Action Indicated (OAI) classification is assigned when significant deficiencies are identified and regulatory action may be considered.
The VAI classification issued to the Verna facility means the FDA is not recommending enforcement action against the plant at this stage and that the facility remains in acceptable regulatory standing.
The inspection also included a Pre-Approval Inspection, a process typically undertaken by the FDA when reviewing manufacturing readiness for products intended for the United States market. Such inspections play a significant role in supporting product approvals and maintaining access to one of the world’s largest pharmaceutical markets.
The outcome is significant for Goa’s pharmaceutical sector, which remains among the state’s largest export-oriented industries. Regulatory findings at major manufacturing facilities can have implications for production schedules, export approvals and supply chains serving international markets.
The Verna plant forms part of Cipla’s wider global manufacturing network that supplies medicines to domestic and overseas markets. The company is among India’s largest pharmaceutical manufacturers and has operations across more than 80 countries, with products spanning respiratory, cardiovascular, anti-infective, anti-retroviral and chronic disease therapies.
The latest outcome also marks an improvement compared to some previous regulatory inspections at the facility. During an inspection in 2022, the Goa plant received six Form 483 observations. More recently, Medispray Laboratories, a Cipla subsidiary located in Kundaim, Goa, received a Form 483 observation following a USFDA inspection in January 2025 before subsequently receiving a VAI classification.
With only two observations recorded during the April 2026 inspection and no enforcement action recommended, the latest classification is expected to provide reassurance regarding the facility’s ongoing operations and exports to the United States market.
Leave a Reply